title: Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen.
authors.forename: Lü
authors.initials: L
authors.lastname: Shuqing
authors.forename: Yang
authors.initials: Y
authors.lastname: Jianmin
authors.forename: Huang
authors.initials: H
authors.lastname: Chongmei
authors.forename: Cheng
authors.initials: C
authors.lastname: Hui
authors.forename: Jianmin
authors.initials: J
authors.lastname: Wang
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D000069286:Bortezomib; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics / Q000532:radiotherapy; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D046988:Proteasome Endopeptidase Complex / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D011719:Pyrazines / Q000008:administration & dosage / Q000494:pharmacology*; D013792:Thalidomide / Q000008:administration & dosage; D015854:Up-Regulation
chemical_list: D020533:Angiogenesis Inhibitors; D001897:Boronic Acids; D009363:Neoplasm Proteins; D011719:Pyrazines; D015251:Epirubicin; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; C088874:PSMB5 protein, human; D046988:Proteasome Endopeptidase Complex